KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $90.1 billion.

  • Amgen's Liabilities and Shareholders Equity fell 81.64% to $90.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $359.2 billion, marking a year-over-year decrease of 340.93%. This contributed to the annual value of $91.8 billion for FY2024, which is 547.07% down from last year.
  • Amgen's Liabilities and Shareholders Equity amounted to $90.1 billion in Q3 2025, which was down 81.64% from $87.9 billion recorded in Q2 2025.
  • Over the past 5 years, Amgen's Liabilities and Shareholders Equity peaked at $97.2 billion during Q4 2023, and registered a low of $59.2 billion during Q1 2022.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $88.7 billion (2023), whereas its average is $78.8 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 805.71% in 2021, then surged by 5223.97% in 2023.
  • Amgen's Liabilities and Shareholders Equity (Quarter) stood at $61.2 billion in 2021, then increased by 6.47% to $65.1 billion in 2022, then surged by 49.19% to $97.2 billion in 2023, then fell by 5.47% to $91.8 billion in 2024, then fell by 1.85% to $90.1 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $90.1 billion for Q3 2025, versus $87.9 billion for Q2 2025 and $89.4 billion for Q1 2025.